Sebelipase Alfa

證據等級: L5

預測適應症: 10 個

Sebelipase Alfa: From Unmarketed Status in Norway to Lysosomal Acid Lipase Deficiency (Wolman Disease / Cholesteryl Ester Storage Disease)

One-Sentence Summary

Sebelipase alfa is not currently on the Norwegian market and has no locally recorded approved indication. The TxGNN model — after filtering out several mechanistically implausible top hits — correctly converges on Lysosomal Acid Lipase Deficiency (LAL-D), spanning the infantile-onset form (Wolman disease) and the later-onset form (Cholesteryl Ester Storage Disease, CESD), supported by 9 clinical trials (including 1 completed Phase 3 RCT) and ~19 publications.

Quick Overview

Item	Content
Original Indication	None on file — not marketed in Norway (data gap). Globally approved as Kanuma® for LAL-D since 2015 (PMID 26452566).
Predicted New Indication	Lysosomal Acid Lipase Deficiency (Wolman disease / Cholesteryl Ester Storage Disease)
TxGNN Prediction Score	~99.7% (Wolman disease 99.72% / CESD 99.72%)
Evidence Level	L2 (1 completed pivotal Phase 3 RCT — ARISE, NCT01757184 — plus multiple long-term cohort/extension studies)
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

The DrugBank-sourced mechanism-of-action field in this evidence pack is a confirmed data gap. However, the literature evidence retrieved for this candidate independently establishes the mechanism: sebelipase alfa is a recombinant human lysosomal acid lipase (rhLAL) enzyme-replacement therapy (Shirley, Drugs 2015, PMID 26452566). It directly supplies the enzyme that is absent or deficient in LAL-D — a 1:1 enzyme-substrate correction, not an indirect similarity heuristic.

This matters because the raw TxGNN ranking (predicted_indications ranks 1–10) is dominated by other lysosomal storage diseases that share phenotypic embedding space but have unrelated deficient enzymes: Scheie/Hurler syndrome (α-L-iduronidase), Gaucher disease (glucocerebrosidase), Tay-Sachs disease (hexosaminidase A). None of these would be corrected by rhLAL, and the evidence pack's own rationale annotations explicitly flag them as mechanistically unsupported (Hold, L5, no clinical evidence). By contrast, Wolman disease and CESD are simply the two ends of the same LAL-D disease spectrum that sebelipase alfa was originally developed for — the trial program listed under "cholesteryl ester storage disease" (rank 4) in fact enrolled both infantile Wolman-disease patients and late-onset CESD patients, which explains why the Wolman-disease entry (rank 5) shows 0 trials in its own record despite having a completed L2/S3 evidence assessment — a database classification artifact rather than an evidence gap.

In practical terms, this "prediction" is not a novel repurposing hypothesis but a re-identification of the drug's own established global indication in a market (Norway) where it currently has no authorization. The clinical utility of this report is therefore less about new pharmacology and more about flagging a market-entry / registration gap.

Clinical Trial Evidence

(Pooled from the CESD/LAL-D trial program, which encompasses both Wolman disease and CESD patients)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01757184	Phase 3	Completed	66	Pivotal randomized placebo-controlled trial (ARISE) of sebelipase alfa 1 mg/kg IV every other week in late-onset LAL-D (CESD)
NCT02112994	Phase 2	Completed	31	Multicenter open-label safety/efficacy study across a broad LAL-D population
NCT02193867	Phase 2	Terminated	10	Weekly infusions up to 3 years in infants with rapidly progressive LAL-D (Wolman disease)
NCT01371825	Phase 2/3	Completed	9	Dose-escalation study in children with growth failure due to LAL-D, weekly dosing up to 5 years
NCT01488097	Phase 2	Completed	8	Extension study evaluating long-term safety/tolerability in adults with LAL-D-related liver dysfunction
NCT01307098	Phase 1/2	Completed	9	First-in-human dose-escalation study in adults with LAL-D-related liver dysfunction
NCT02376751	N/A	No longer available	N/A	Expanded access protocol for LAL-D patients pending commercial availability
NCT02926872	N/A	Terminated	22	DETECT: screening for LAL-D as underlying cause of pediatric liver injury
NCT04532047	Phase 1	Recruiting	10	PEARL basket trial: in-utero enzyme replacement feasibility across multiple LSDs (not LAL-D specific; low direct relevance)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34774639	2022	RCT (extension)	Journal of Hepatology	Final results of Phase 3 ARISE study; sebelipase alfa efficacy/safety in children and adults with LAL-D
35442238	2022	Cohort	J Pediatr Gastroenterol Nutr	Long-term treatment outcomes from single-arm open-label study (NCT02112994)
34906190	2021	Cohort (10-yr)	Orphanet J Rare Dis	Nationwide cohort of ERT in Wolman disease with up to 10 years of follow-up
29628368	2018	Cohort	J Clin Lipidol	Sebelipase alfa improves atherogenic biomarkers (Phase 3 ARISE data)
38918870	2024	Case series	Orphanet J Rare Dis	Twice-weekly dosing rescues severely ill infants with Wolman disease
28179030	2017	Open-label dose-escalation	Orphanet J Rare Dis	Survival outcomes in infants treated with sebelipase alfa
33407676	2021	Long-term follow-up	Orphanet J Rare Dis	Long-term survival with sebelipase alfa in rapidly progressive LAL-D (final results, 2 open-label studies)
40781810	2025	Registry	Liver International	International registry data: sebelipase alfa improves aminotransferase levels
39770929	2024	Review	Nutrients	Practical diagnosis/management recommendations for LAL-D, focus on Wolman disease
26452566	2015	Review	Drugs	Sebelipase alfa: first global approval

Norway Market Information

Sebelipase alfa currently holds no marketing authorization in Norway and no license records are available in the evidence pack (total_licenses: 0).

Safety Considerations

Please refer to the package insert for safety information.

Note: The evidence base independently indicates infusion-associated hypersensitivity is a known clinical concern with sebelipase alfa (e.g., PMID 38572778 describes a 14-step desensitization protocol for a Wolman-disease patient), but no structured warnings, contraindications, or DDI data are present in the DrugBank-sourced safety fields of this evidence pack (DG001, blocking severity).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The core drug-disease pairing (sebelipase alfa → LAL-D/Wolman disease/CESD) is mechanistically direct and backed by a completed pivotal Phase 3 RCT (ARISE) plus multiple long-term cohort and registry studies — this is in fact the drug's own globally approved indication (Kanuma®, approved since 2015), not a speculative repurposing hypothesis. However, the drug is entirely unmarketed in Norway and this specific evidence pack is missing safety/label data, so the appropriate next step is a guarded regulatory-entry pathway rather than an unconditional "Go."

To proceed, the following is needed:

TFDA/Norwegian-equivalent label data — key warnings, contraindications (DG001, blocking; requires PDF label retrieval)
Structured DrugBank MOA record (DG002)
Formal Norway market authorization / import license assessment, since the drug has no local regulatory footprint
Explicit exclusion of the other TxGNN top-10 candidates (Scheie syndrome, Hurler syndrome, growth hormone insensitivity syndrome, Gaucher disease, lysosomal storage disease with skeletal involvement, autosomal ichthyosis syndrome, Tay-Sachs disease, benign adrenal neoplasm) from further review — all lack mechanistic plausibility and supporting evidence per the rationale annotations in this pack
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.